APYX MEDICAL CORPORATION RELEASES ENVIRONMENTAL, SOCIAL AND GOVERNANCE DATA IN NEW TEAR SHEETBy ApyxMedical|2025-12-12T19:15:08+00:00July 27, 2022|
RENUVION CLEARED BY FDA FOR NECK LAXITY PROCEDURES OFFERING PATIENTS A MINIMALLY INVASIVE OPTION TO ELIMINATE SAGGING NECKBy ApyxMedical|2025-12-12T19:15:31+00:00July 18, 2022|
APYX MEDICAL CORPORATION RECEIVES FDA 510(K) CLEARANCE FOR THE USE OF RENUVION TO IMPROVE APPEARANCE OF LAX (LOOSE) SKINBy ApyxMedical|2025-12-12T19:15:55+00:00July 18, 2022|
APYX MEDICAL CORPORATION ANNOUNCES RESULTS OF THE U.S. IDE CLINICAL STUDY EVALUATING THE USE OF RENUVION TO IMPROVE THE APPEARANCE OF LAX SKIN IN THE NECK AND SUBMENTAL REGIONBy ApyxMedical|2025-12-12T19:16:26+00:00July 8, 2022|
